Loading...
BVMF
FLRY3
Market cap1.21bUSD
May 15, Last price  
12.65BRL
1D
-0.16%
1Q
1.61%
Jan 2017
-28.25%
IPO
-16.99%
Name

Fleury SA

Chart & Performance

D1W1MN
P/E
11.19
P/S
0.90
EPS
1.13
Div Yield, %
3.83%
Shrs. gr., 5y
9.90%
Rev. gr., 5y
21.48%
Revenues
7.68b
+18.76%
487,588,000551,230,000675,280,000770,109,000871,541,0001,125,741,0001,501,783,0001,656,896,0001,678,900,0001,894,960,0002,096,113,0002,383,012,0002,664,463,0002,905,107,0002,971,616,0003,872,651,0004,463,040,0006,470,850,0007,684,659,000
Net income
616m
+45.41%
32,112,00025,315,00041,962,00083,685,000130,001,000100,647,000106,588,00061,143,00085,802,000107,343,000228,749,000320,618,000331,585,000312,317,000256,961,000349,926,000307,908,000423,758,000616,172,000
CFO
1.93b
+34.13%
71,329,00079,480,00072,398,00024,031,000112,919,000145,960,000167,054,000209,585,000285,709,000368,922,000513,870,000529,607,000701,485,000732,317,000647,141,0001,018,669,000987,133,0001,439,304,0001,930,488,000
Dividend
Aug 15, 20240.33738 BRL/sh
Earnings
Aug 06, 2025

Profile

Fleury S.A., together with its subsidiaries, provides medical services in the diagnostic, treatment, clinical analysis, health management, medical care, orthopedics, and ophthalmology areas in Brazil. The company operates through three segments: Diagnostic Medicine, Integrated Medicine, and Dental. It provides laboratory and image exam, diagnostic information, check-up and reference laboratory, genomics, clinic day, center of infusions, dental imaging exam, dental radiology, and diagnostic imaging services. The company also offers Saúde I, a digital healthcare platform that provides services, including teleconsultations, medical, diagnostic medicine exams, and procedures; and corporate solutions and face-to-face primary care, as well as solutions for physicians with digital office and medical education. It operates 284 customer service units and 31 hospital-based units under the Labs a+, Felippe Mattoso, Lafe, Fleury, a+SP, CIP, Moacir Cunha, Vita, inlab, Weinmann, Serdil, a+ and Diagmax, a+, IRN / CPC, Diagnosis a+, a+BA, and Pretti and Bioclinic brand names. The company was founded in 1926 and is headquartered in São Paulo, Brazil.
URL
https://www.fleury.com.br/
IPO date
Dec 16, 2009
Employees
Domiciled in
BR
Incorporated in
BR

Valuation

Title
BRL in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
7,684,659
18.76%
6,470,850
44.99%
4,463,040
15.25%
Cost of revenue
5,795,722
5,073,471
3,388,633
Unusual Expense (Income)
NOPBT
1,888,937
1,397,379
1,074,407
NOPBT Margin
24.58%
21.59%
24.07%
Operating Taxes
182,757
110,505
96,662
Tax Rate
9.68%
7.91%
9.00%
NOPAT
1,706,180
1,286,874
977,745
Net income
616,172
45.41%
423,758
37.62%
307,908
-12.01%
Dividends
(343,362)
(510,109)
(337,201)
Dividend yield
5.23%
5.90%
7.01%
Proceeds from repurchase of equity
(20,915)
(19,380)
1,042,867
BB yield
0.32%
0.22%
-21.67%
Debt
Debt current
497,611
580,162
535,820
Long-term debt
6,180,442
5,092,363
4,260,514
Deferred revenue
Other long-term liabilities
302,770
1,121,395
287,609
Net debt
6,470,137
4,504,987
3,486,844
Cash flow
Cash from operating activities
1,930,488
1,439,304
987,133
CAPEX
(488,115)
(413,811)
(413,086)
Cash from investing activities
(2,056,630)
2,413
(1,384,473)
Cash from financing activities
126,010
(1,437,053)
380,874
FCF
1,802,182
169,425
497,684
Balance
Cash
2,341,743
924,133
1,309,490
Long term investments
(2,133,827)
243,405
Excess cash
843,996
1,086,338
Stockholders' equity
3,454,476
5,150,532
2,117,844
Invested Capital
11,069,163
9,629,518
5,580,441
ROIC
16.49%
16.92%
19.72%
ROCE
15.98%
13.34%
15.15%
EV
Common stock shares outstanding
544,280
484,470
338,929
Price
12.07
-32.42%
17.86
25.77%
14.20
-7.73%
Market cap
6,569,456
-24.08%
8,652,634
79.78%
4,812,789
-7.20%
EV
13,125,356
13,185,240
8,319,182
EBITDA
2,668,920
2,072,757
1,529,746
EV/EBITDA
4.92
6.36
5.44
Interest
531,681
494,568
406,851
Interest/NOPBT
28.15%
35.39%
37.87%